Related Experiment Video
Updated: Apr 12, 2026
04:37
Comprehensive Analysis of Procoagulant Platelets Exhibiting Features of Necrosis, Apoptosis and Platelet Activation
Published on: May 23, 2025
1.3K
Genetically Determined Platelet Reactivity and Related Clinical Implications
Teresa Strisciuglio1, Giuseppe Di Gioia, Chiara De Biase
1Divisione di Cardiologia, Dipartimento di Scienze Biomediche Avanzate, Università Federico II Napoli, Naples, Italy.
Summary
Genetic variations impact antiplatelet drug effectiveness, leading to high on-treatment platelet reactivity. This review explores genetic polymorphisms influencing optimal platelet inhibition in patients undergoing cardiovascular procedures.
Area of Science:
- Cardiovascular Medicine
- Pharmacogenomics
- Hematology
Background:
- Antiplatelet drugs are crucial for patients with acute coronary syndromes and after percutaneous coronary intervention.
- Genetic mutations in drug targets cause variable patient responses to antiplatelet therapy.
- High on-treatment platelet reactivity (HTPR) is linked to adverse cardiovascular events like re-infarction and stroke.
Purpose of the Study:
- To review current evidence on genetic polymorphisms affecting antiplatelet drug efficacy.
- To examine the role of genetic variations in achieving optimal platelet inhibition.
- To discuss the clinical implications of genetic factors on antiplatelet treatment outcomes.
Main Methods:
- Literature review of studies investigating genetic polymorphisms and antiplatelet response.
- Analysis of data on genetic variations in platelet receptors and enzymes.
- Examination of clinical outcomes associated with different genetic profiles.
Main Results:
- Specific genetic polymorphisms are associated with reduced platelet inhibition by common antiplatelet agents.
- Inter-individual variability in response to antiplatelet therapy is significantly influenced by genetic factors.
- Identification of genetic markers could potentially predict HTPR and guide treatment decisions.
Conclusions:
- Genetic polymorphisms play a significant role in the efficacy of antiplatelet therapy.
- Understanding these genetic factors is essential for optimizing treatment and improving patient prognosis.
- Further research is needed to determine the clinical utility of routine genetic testing for antiplatelet therapy.
Related Concept Videos
01:22Formation of the Platelet Plug
10.9K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.9K
01:18Structure and Function of Platelets
6.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
6.2K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
126
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
126
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.5K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.5K
01:16Drug toxicity: Idiosyncratic Reactions
197
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
197